Biogen Inc. Form 8-K Filing

Biogen Inc. (Biogen) anticipates that its GAAP and non-GAAP results for the first quarter of 2026 will reflect approximately $34 million in pre-tax acquired in-process research and development, upfront, and milestone expenses. This is expected to reduce the diluted earnings per share for both GAAP and non-GAAP measures by approximately $0.19. These expenses are associated with collaboration and license agreements. Biogen does not typically forecast these specific expenses due to their unpredictable nature. The company notes that the results for the quarter ended March 31, 2026, are preliminary and subject to finalization, and actual results may differ. The filing includes forward-looking statements regarding these estimates, which are subject to risks and uncertainties.